Involvement of the renin-angiotensin system in migraine

Journal of Hypertension

Volumn 24, Issue SUPPL. 1, 2006, Pages

  Tronvik, Erling ^a   Stovner, Lars J ^a   Schrader, Harald ^a   Bovim, Gunnar ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Angiotensin II receptor blockers; Blood pressure; Migraine; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; ERGOTAMINE; IRBESARTAN; LISINOPRIL; LISURIDE; LOSARTAN; METHYSERGIDE; NITRIC ACID DERIVATIVE; PIZOTIFEN; PLACEBO; PROPRANOLOL; TASOSARTAN; TELMISARTAN; TRIPTAN DERIVATIVE; VALSARTAN; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

CLINICAL TRIAL; COUGHING; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSAGE FORM; FATIGUE; GENETIC ANALYSIS; HEADACHE; HUMAN; META ANALYSIS; MIGRAINE; MONARTHRITIS; PRIORITY JOURNAL; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYNCOPE; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; GENETICS; PHYSIOLOGY;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; HUMANS; MIGRAINE DISORDERS; PEPTIDYL-DIPEPTIDASE A; PPAR GAMMA; RENIN-ANGIOTENSIN SYSTEM;

EID: 33745543021     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000220419.86149.11     Document Type: Review

References (36)

1. Phillips P. Migraine as a woman's issue - will research and new treatments help? JAMA 1998; 280:1975-1976.
2. Berg J, Stovner LJ. Cost of migraine and other headaches in Europe. Eur J Neurol 2005; 12:59-62.
3. Hagen K, Stovner LJ, Vatten L, Holmen J, Zwart JA, Bovim G. Blood pressure and risk of headache: a prospective study of 22 685 adults in Norway. J Neurol Neurosurg Psychiatry 2002; 72:463-466.
4. Sicuteri F. Enkephalinase inhibition relieves pain syndromes of central dysnociception (migraine and related headache). Cephalalgia 1981; 1:229-232.
5. Spillantini MG, Panconesi A, Del Bianco PL, Sicuteri F. Enkephalinase and angiotensin converting enzyme activities in human venous and arterial plasma. Neuropeptides 1986; 8:111-117.
6. Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache 1995; 35:470-471.
7. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322:19-22.
8. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker (candesartan cilexetil): a randomized, placebo controlled, crossover study. JAMA 2003; 289:65-69.
9. Etminan M, Mitchell A, Levine MA, Tomlinson G, Rochon PA. Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis. Am J Med 2002; 112:642-646.
10. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC. Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy - a pilot study. Pharmacoepidemiol Drug Saf 2004; 13:41-47.
11. Onder G, Pahor M, Gambassi G, Federici A, Savo A, Carbonin P, Bernabei R. Association between ACE inhibitors use and headache caused by nitrates among hypertensive patients: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). Cephalalgia 2003; 23:901-906.
12. Paterna S, Di Pasquale P, D'Angelo A, Seidita G, Tuttolomondo A, Cardinale A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 2000; 43:133-136.
13. Kowa H, Fusayasu E, Ijiri T, Ishizaki K, Yasui K, Nakaso K, et al. Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neurosci Lett 2005; 374:129-131.
14. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet 2000; 96:762-764.
15. Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 1997; 120:2171-2177.
16. Evers S, Koch HG, Husstedt I-W. Plasma homocysteine levels in primary headache. In: Olesen J, Edvinsson L, editors. Headache pathogenesis: monoamines, neuropeptides, purines and nitric oxide. Philadelphia: Lippincott-Raven Publishers; 1997, pp. 215-218.
17. Lea RA, Ovcaric M, Sundholm J, Solyom L, MacMillan J, Griffiths LR. Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate reductase may act in combination to increase migraine susceptibility. Mol Brain Res 2005; 136:112-117.
18. Martelletti P, Cugini P, Letizia C, Di Palma L, Battisti P, Granata M, et al. Chronopathology for angiotensin converting enzyme circadian rhythm in migraine. Chronobiologia 1990; 17:59-64.
19. Kaneko S, Mori A, Tamura S, Satoh M, Takagi H. Intracerebroventricular administration of angiotensin II attenuates morphine-induced analgesia in mice. Neuropharmacology 1985; 24:1131-1134.
20. Haulica I, Neamtu C, Stratone A, Petrescu G, Branisteanu D, Rosca V, Slatineanu S. Evidence for the involvement of cerebral renin-angiotensin system (RAS) in stress analgesia. Pain 1986; 27:237-245.
21. Irvine RJ, White JM, Head RJ. The renin angiotensin system and nociception in spontaneously hypertensive rats. Life Sci 1995; 56:1073-1078.
22. Norman JA, Autry WL, Barbaz BS. Angiotensin-converting enzyme inhibitors potentiate the analgesic activity of [Met]-enkephalin-Arg6-Phe7 by inhibiting its degradation in mouse brain. Mol Pharmacol 1985; 28:521-526.
23. Pelegrini-da-Silva A, Martins AR, Prado WA. A new role for the renin-angiotensin system in the rat periaqueductal gray matter: angiotensin receptor-mediated modulation of nociception. Neuroscience 2005; 132:453-463.
24. Takai S, Song K, Tanaka T, Okunishi H, Miyazaki M. Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Life Sci 1996; 59:331-336.
25. Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Rev 2005; 48:438-456.
26. Davisson LR. Physiological genomic analysis of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2003; 285:498-511.
27. Saavedra JM. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 2005; 25:485-512.
28. Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol 1993; 50:825-830.
29. 1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000; 31:2478-2486.
30. Allen AM, Moeller I, Jenkins TA, Zhuo J, Aldred GP, Chai SY, Mendelsohn FA. Angiotensin receptors in the nervous system. Brain Res Bull 1998; 47:17-28.
31. Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002; 51:507-516.
32. 2 receptors: Studies with AT1 receptor-knockout mice. J Am Soc Nephrol 2002; 13:1162-1171.
33. Kurtz TW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferators-activated receptor-gamma activator. Acta Diabetol 2005; 42:9-16.
34. Kintscher U, Unger T. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers. Acta Diabetol 2005; 42:26-32.
35. Garcia-Bueno B, Madrigal JL, Lizasoain I, Moro MA, Lorenzo P, Leza JC. Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol Psychiatry 2005; 57:885-894.
36. Benani A, Heurtaux T, Netter P, Minn A. Activation of peroxisome proliferators-activated receptor alpha in rat spinal cord after peripheral noxious stimulation. Neurosci Lett 2004; 369:59-63.